SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
0.7426 USD   +0.26%
05/17SPECTRUM PHARMACEUTICALS INC Change in Directors or Principal Officers (form 8-K/A)
AQ
05/17SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
05/17Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI

08/09/2021 | 08:34pm EDT

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI).  Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Spectrum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration regarding the Company's Biologics License Application for ROLONTIS® (eflapegrastim).  The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility will be necessary. 

On this news, Spectrum's stock price fell $0.70 per share, or 21.54%, to close at $2.55 per share on August 6, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com 
888-476-6529 ext. 7980

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-spectrum-pharmaceuticals-inc---sppi-301351515.html

SOURCE Pomerantz LLP


© PRNewswire 2021
All news about SPECTRUM PHARMACEUTICALS, INC.
05/17SPECTRUM PHARMACEUTICALS INC Change in Directors or Principal Officers (form 8-K/A)
AQ
05/17SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
AQ
05/17Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
BU
05/12TRANSCRIPT : Spectrum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12SPECTRUM PHARMA : Q1 Earnings Snapshot
AQ
05/12Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corp..
BU
05/12Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
05/11Spectrum Pharmaceuticals Names Nora Brennan CFO
MT
05/11Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
BU
05/11Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer
CI
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations